Share

Pharmacological inhibition of glyoxalase-1 (Glo-1) as a new therapeutic strategy to enhance the antitumor effect of trabectedin in preclinical models of soft tissue sarcoma

Project objectives

  • Evaluation of the antitumor effect of the specific Glo-1 inhibitor, Sp-bromobenzylglutathione cyclopentyl diester (BBGC), in combination with trabectedin, in different cellular models of soft tissue sarcoma 
  • Evaluation of the antitumor effect of BBGC, in combination with trabectedin, in a myxoid liposarcoma model sensitive and resistant to trabectedin
  • Analysis of the anti-tumor effect of the pharmacological combination, BBGC + trabectedin, in mouse models of sarcomas

Start and end date
December 2017 – ongoing (December 2023 approximate end date)

Project Manager
Bruno Vincenzi (PI)

Coordinating institution of the project
Università Campus Bio-Medico di Roma

Other Institutions involved
  • IRCCS Rizzoli Orthopedic Institute
  • IRCCS National Cancer Institute Foundation

Primary funding source
PharmaMar SA
2023© Università Campus Bio-Medico di Roma, Via Álvaro del Portillo, 21 - 00128 Rome, Tel. +39 06.22541.1, Fax +39 06.22541.456, VAT number: 048 020 51 005, Fiscal Code: 97087620585
QUICK LINKS
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
magnifiercrossmenuchevron-downchevron-leftchevron-right